AxoGen (NASDAQ:AXGN – Get Free Report) and Venus Concept (NASDAQ:VERO – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.
Profitability
This table compares AxoGen and Venus Concept’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AxoGen | -13.21% | -9.63% | -6.26% |
| Venus Concept | -92.76% | -1,904.25% | -85.22% |
Valuation & Earnings
This table compares AxoGen and Venus Concept”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AxoGen | $225.21 million | 10.84 | -$15.70 million | ($0.64) | -71.70 |
| Venus Concept | $58.88 million | 0.01 | -$47.00 million | ($48.84) | -0.01 |
AxoGen has higher revenue and earnings than Venus Concept. AxoGen is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
80.3% of AxoGen shares are owned by institutional investors. Comparatively, 87.4% of Venus Concept shares are owned by institutional investors. 2.4% of AxoGen shares are owned by insiders. Comparatively, 28.0% of Venus Concept shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Volatility and Risk
AxoGen has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Venus Concept has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and price targets for AxoGen and Venus Concept, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AxoGen | 1 | 1 | 9 | 0 | 2.73 |
| Venus Concept | 1 | 0 | 0 | 0 | 1.00 |
AxoGen currently has a consensus target price of $46.50, indicating a potential upside of 1.33%. Given AxoGen’s stronger consensus rating and higher probable upside, research analysts plainly believe AxoGen is more favorable than Venus Concept.
Summary
AxoGen beats Venus Concept on 11 of the 14 factors compared between the two stocks.
About AxoGen
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
About Venus Concept
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.
